Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies

Simona Soverini, Caterina De Benedittis, Katerina Machova Polakova, Adela Brouckova, Cristina Papayannidis, Paola Bresciani, Valeria Coluccio, Ilaria Iacobucci, Claudia Venturi, Mario Luppi, Emanuela Ottaviani, Federica Cattina, Robin Foà, MD, Antonella Vitale, Domenico Russo, Michele Baccarani, MD, Giovanni Martinelli

Blood (2012) 120 (21): 284.

https://doi.org/10.1182/blood.V120.21.284.284

Published: 2012

Journal Articles

Single Cell Network Profiling (SCNP) of Early-Stage Chronic Lymphocytic Leukemia (CLL): Association with p53, IGHV Mutational Status and Time to First Treatment (TTFT)

Jason Ptacek, PhD, Erik Evensen, Rachael E. Hawtin, Ph.D., Greg Friedland, Jodi R. Ware, PharmD, James Cordeiro, Nadia Peragine, Ph.D, Alessandra Cesano, M.D., Ph.D., Robin Foà, MD, Anna Guarini, PhD

Blood (2012) 120 (21): 1783.

https://doi.org/10.1182/blood.V120.21.1783.1783

Published: 2012

Journal Articles

NOTCH1 , SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment

Sabina Chiaretti, MD, PhD, Marilisa Marinelli, PhD, Ilaria Del Giudice, MD, PhD, Silvia Bonina, PhD student, Sara Gabrielli, Miss, Alfonso Piciocchi, Monica Messina, PhD, Marco Vignetti, MD, Davide Rossi, MD, PhD, Valeria Di Maio, Miss, Francesca Romana Mauro, MD, Anna Guarini, PhD, Gianluca Gaidano, MD, PhD, Robin Foà, MD

Blood (2012) 120 (21): 1784.

https://doi.org/10.1182/blood.V120.21.1784.1784

Published: 2012

Journal Articles

Targeting Metabolic Pathways for Leukemia Treatment

Simone Mirabilii, Maria Rosaria Ricciardi, Matteo Allegretti, Roberto Licchetta, Stefano Iacovelli, Paola Bergamo, Maria Teresa Petrucci, Raffaella Nicolai, Gianfranco Peluso, Robin Foà, MD, Giuliana Alimena, Agostino Tafuri

Blood (2012) 120 (21): 1371.

https://doi.org/10.1182/blood.V120.21.1371.1371

Published: 2012

Journal Articles

Clinical Relevance of an Extended Diagnostic Work-Out in Patients with Primary Autoimmune Amolytic Anemia (AIHA)

Francesca R Mauro, MD, PhD, Daniele Armiento, MD, Serelina Coluzzi, MD, Maria S De Propris, PhD, Francesca Paoloni, BS, Gianluca Giovannetti, MD, Matteo Molica, MD, Luisa Quattrocchi, MD, Michelina Santopietro, MD, Chiara Spadafora, Lucia Granati, MD, Mara Riminucci, MD, Anna Guarini, PhD, Gabriella Girelli, MD, Robin Foà, MD

Blood (2012) 120 (21): 3192.

https://doi.org/10.1182/blood.V120.21.3192.3192

Published: 2012

Journal Articles

Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia

Blood (2012) 120 (21): 712.

https://doi.org/10.1182/blood.V120.21.712.712

Published: 2012

Journal Articles

Role of PET/CT in the Diagnostic Work-up of Patients with Chronic Lymphocytic Leukemia (CLL) and Clinical Signs of Disease Progression

Francesca R Mauro, MD, PhD, Mara Riminucci, MD, Davide Rossi, MD, PhD, Francesca Paoloni, BS, Luca Laurenti, MD, Anna M Frustaci, MD, Giuseppe Cimino, MD, Michelina Santopietro, MD, Chiara Spadafora, Angela Rago, M.D., Francesco Autore, MD, Molica Matteo, MD, Brocchieri Simonetta, MD, Emanuele Nicolai, MD, Gianluca Gaidano, MD, PhD, Anna Guarini, PhD, Bianco Paolo, MD, Robin Foà, MD

Blood (2012) 120 (21): 3888.

https://doi.org/10.1182/blood.V120.21.3888.3888

Published: 2012

Journal Articles

Clinical Characteristics and Predictive Factors of Peripheral Neurophaty in Multiple Myeloma Patients Treated with Bortezomib and/or Imids

Vincenzo Federico, MD, Russo Eleonora, MD, PhD, Andrea Truini, MD, Anna Levi, MD, PhD, Fabiana Gentilini, MD, Giulia Biagioli, Caterina Leoni, MD, Robin Foà, MD, Maria Teresa Petrucci, MD

Blood (2012) 120 (21): 4056.

https://doi.org/10.1182/blood.V120.21.4056.4056

Published: 2012

Journal Articles

Iron Chelation Therapy with Deferasirox In Transfusion Dependent Myelodysplastic Syndrome Patients. Preliminary Report From the Prospective MDS0306 GIMEMA Trial

Blood (2010) 116 (21): 2928.

https://doi.org/10.1182/blood.V116.21.2928.2928

Published: 2010

Journal Articles

Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five Versus Seven Consecutive Days) In Patients with Hairy Cell Leukemia (HCL) In the ICGHCL2004 Protocol by the Italian Cooperative Group on Hcl

Blood (2010) 116 (21): 701.

https://doi.org/10.1182/blood.V116.21.701.701

Published: 2010

Journal Articles

The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status

Marta Coscia, MD, PhD, Candida Vitale, MD, Silvia Peola, PhD, Chiara Riganti, MD, Daniela Angelini, PhD, Myriam Foglietta, MD, Francesca Pantaleoni, PhD, Giorgia Matta, MD, Sabina Chiaretti, MD, Anna Guarini, PhD, Daniela Drandi, PhD, Marco Ladetto, MD, Amalia Bosia, MD, Luca Battistini, MD, Robin Foà, MD, Mario Boccadoro, MD, Jean-Jacques Fournié, PhD, Massimo Massaia, MD

Blood (2010) 116 (21): 3602.

https://doi.org/10.1182/blood.V116.21.3602.3602

Published: 2010

Journal Articles

Bcl-2 and mTOR as Effective Targets for Molecular Therapy of Acute Lymphoblastic Leukemia

Stefano Iacovelli, Maria Rosaria Ricciardi, PhD, Andrea Miele, Paola Bergamo, Roberto Licchetta, Antonella Vitale, MD, Anna Testi, MD, Maria Teresa Petrucci, MD, Michele Milella, MD, Robin Foà, MD, Agostino Tafuri, MD

Blood (2010) 116 (21): 3228.

https://doi.org/10.1182/blood.V116.21.3228.3228

Published: 2010

Journal Articles

Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial

Blood (2010) 116 (21): 1360.

https://doi.org/10.1182/blood.V116.21.1360.1360

Published: 2010

Journal Articles

Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL)

Blood (2010) 116 (21): 1369.

https://doi.org/10.1182/blood.V116.21.1369.1369

Published: 2010

Journal Articles

Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0)

Blood (2010) 116 (21): 1371.

https://doi.org/10.1182/blood.V116.21.1371.1371

Published: 2010

Journal Articles

Fludarabine, Cyclophosphamide and Lenalidomide (FCL) for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL): Results of the Dose-Finding Phase of the GIMEMA LLC606 Study

Francesca Romana Mauro, MD, Daniele Armiento, MD, Sonia Orlando, BS, Ilaria Del Giudice, MD, Maria Stefania De Propriis, PhD, Mauro Nanni, PhD, Marilisa Marinelli, PhD, Molica Matteo, Paola Fazi, MD, Francesca Paoloni, BS, Graziosi Antonietta, Laura Collada, Anna Guarini, PhD, Robin Foà, MD

Blood (2010) 116 (21): 1377.

https://doi.org/10.1182/blood.V116.21.1377.1377

Published: 2010

Journal Articles

Analysis of Stereotyped IGHV Distribution In a Series of 1133 Chronic Lymphocytic Leukemia Patients: The Experience of a Multicenter Italian Study Group

Francesco Maura, Giovanna Cutrona, PhD, Massimo Gentile, Serena Matis, PhD, Monica Colombo, Luca Agnelli, Giacomo Tuana, Rosanna Massara, Fabrizio Loiacono, Simona Pedemonte, Daniele Reverberi, Emanuela Anna Pesce, Marta Lionetti, PhD, Sonia Fabris, PhD, Anna Grazia Recchia, Francesco Di Raimondo, MD, Caterina Musolino, MD, Marco Gobbi, Nicola Di Renzo, MD, Francesca Romana Mauro, Renato Cantaffa, Maura Brugiatelli, MD, Francesco Merli, MD, Simonetta Zupo, Caterina Mammi, Luca Baldini, Francesco Angrilli, MD, Gianni Quintana, Ugo Consoli, MD, Giovanni Bertoldero, MD, Emilio Iannitto, MD, Paolo Di Tonno, Antonio Fragasso, Stefano Molica, MD, Pellegrino Musto, MD, Maria Cristina Cox, Gianluca Festini, Vincenzo Callea, MD, Stefano Sacchi, Giorgio Lambertenghi Deliliers, MD, Robin Foà, MD, Massimo Federico, MD, Agostino Cortelezzi, MD, Fortunato Morabito, Manlio Ferrarini, Antonino Neri, MD

Blood (2010) 116 (21): 2423.

https://doi.org/10.1182/blood.V116.21.2423.2423

Published: 2010

Journal Articles

Phenotypic and Functional Features of Vγ9/Vδ2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells.

Marta Coscia, MD, Silvia Peola, PhD, Giorgia Matta, MD, Francesca Pantaleoni, PhD, Myriam Foglietta, MD, Daniela Angelini, PhD, Sabina Chiaretti, MD, Chiara Riganti, MD, Anna Guarini, PhD, Daniela Drandi, PhD, Marco Ladetto, MD, Amalia Bosia, MD, Robin Foà, MD, Luca Battistini, MD, Mario Boccadoro, MD, Jean Jacques Fournie, PhD, Massimo Massaia, MD

Blood (2007) 110 (11): 1131.

https://doi.org/10.1182/blood.V110.11.1131.1131

Published: 2007

Journal Articles

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m 2 (Mel200) Versus Melphalan 100 mg/m 2 (Mel100) in Newly Diagnosed Myeloma Patients.

Blood (2007) 110 (11): 727.

https://doi.org/10.1182/blood.V110.11.727.727

Published: 2007

Journal Articles

What Have We Learned from Measuring Health-Related Quality of Life in Patients with Chronic Lymphocytic Leukemia? A Systematic Review of Published Studies from 1990 to 2007.

Stefano Molica, MD, Francesca Mauro, MD, Marco Vignetti, MD, Robin Foà, MD, Fabio Efficace, PhD

Blood (2007) 110 (11): 4718.

https://doi.org/10.1182/blood.V110.11.4718.4718

Published: 2007

NARROW

Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies

Single Cell Network Profiling (SCNP) of Early-Stage Chronic Lymphocytic Leukemia (CLL): Association with p53, IGHV Mutational Status and Time to First Treatment (TTFT)

NOTCH1 , SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment

Targeting Metabolic Pathways for Leukemia Treatment

Clinical Relevance of an Extended Diagnostic Work-Out in Patients with Primary Autoimmune Amolytic Anemia (AIHA)

Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia

Role of PET/CT in the Diagnostic Work-up of Patients with Chronic Lymphocytic Leukemia (CLL) and Clinical Signs of Disease Progression

Clinical Characteristics and Predictive Factors of Peripheral Neurophaty in Multiple Myeloma Patients Treated with Bortezomib and/or Imids

Iron Chelation Therapy with Deferasirox In Transfusion Dependent Myelodysplastic Syndrome Patients. Preliminary Report From the Prospective MDS0306 GIMEMA Trial

Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five Versus Seven Consecutive Days) In Patients with Hairy Cell Leukemia (HCL) In the ICGHCL2004 Protocol by the Italian Cooperative Group on Hcl

The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status

Bcl-2 and mTOR as Effective Targets for Molecular Therapy of Acute Lymphoblastic Leukemia

Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial

Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL)

Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0)

Fludarabine, Cyclophosphamide and Lenalidomide (FCL) for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL): Results of the Dose-Finding Phase of the GIMEMA LLC606 Study

Analysis of Stereotyped IGHV Distribution In a Series of 1133 Chronic Lymphocytic Leukemia Patients: The Experience of a Multicenter Italian Study Group

Phenotypic and Functional Features of Vγ9/Vδ2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells.

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m 2 (Mel200) Versus Melphalan 100 mg/m 2 (Mel100) in Newly Diagnosed Myeloma Patients.

What Have We Learned from Measuring Health-Related Quality of Life in Patients with Chronic Lymphocytic Leukemia? A Systematic Review of Published Studies from 1990 to 2007.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only